Empirical Finance LLC purchased a new stake in Emergent BioSolutions Inc. (NYSE:EBS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 14,083 shares of the biopharmaceutical company’s stock, valued at approximately $887,000.
A number of other large investors have also recently made changes to their positions in the business. Ameritas Investment Partners Inc. grew its position in shares of Emergent BioSolutions by 1.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 16,291 shares of the biopharmaceutical company’s stock valued at $1,026,000 after purchasing an additional 170 shares during the period. Fifth Third Bancorp grew its holdings in Emergent BioSolutions by 2.3% in the 1st quarter. Fifth Third Bancorp now owns 8,591 shares of the biopharmaceutical company’s stock valued at $798,000 after buying an additional 196 shares in the last quarter. Tlwm grew its holdings in Emergent BioSolutions by 4.5% in the 1st quarter. Tlwm now owns 4,705 shares of the biopharmaceutical company’s stock valued at $437,000 after buying an additional 201 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Emergent BioSolutions by 5.4% during the 2nd quarter. Exchange Traded Concepts LLC now owns 4,233 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 216 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in Emergent BioSolutions by 2.1% in the first quarter. Thrivent Financial for Lutherans now owns 12,044 shares of the biopharmaceutical company’s stock valued at $1,119,000 after buying an additional 250 shares in the last quarter. 83.12% of the stock is owned by hedge funds and other institutional investors.
Shares of EBS stock opened at $57.24 on Wednesday. The business’s fifty day simple moving average is $61.97 and its 200-day simple moving average is $68.05. The company has a market cap of $3.07 billion, a PE ratio of 10.33 and a beta of 0.91. The company has a current ratio of 3.08, a quick ratio of 2.05 and a debt-to-equity ratio of 0.53. Emergent BioSolutions Inc. has a 12-month low of $55.07 and a 12-month high of $127.20.
Several equities research analysts recently commented on the company. Zacks Investment Research raised Emergent BioSolutions from a “strong sell” rating to a “hold” rating and set a $65.00 target price for the company in a research note on Tuesday, June 22nd. TheStreet cut Emergent BioSolutions from a “b-” rating to a “c” rating in a research report on Thursday, July 29th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Emergent BioSolutions has an average rating of “Buy” and an average target price of $90.20.
Emergent BioSolutions Profile
Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.
Featured Story: Why Invest in Dividend Kings
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.